{"data":{"id":1334,"lang":"en","title":"Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Expanding Rare Disease Portfolio","summary":"Neurocrine Biosciences announced a $2.9 billion cash deal to buy Soleno Therapeutics, gaining VYKAT XR, the first-in-class treatment for Prader-Willi syndrome.","category":"business","category_label":"Business","published_at":"2026-04-07T12:03:38Z","updated_at":"2026-04-07T12:03:38Z","url":"https://techtools.cz/tools/news/article/1334-neurocrine-biosciences-to-acquire-soleno-therapeutics-for-2-9-billion-expanding","api_url":"https://techtools.cz/news-api/v1/articles/1334?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/1334.md?lang=en","image_url":"https://s.yimg.com/ny/api/res/1.2/haS1ZbHwSrV.E.59QsJonQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD05OTQ-/https://media.zenfs.com/en/reuters.com/55ec3cb2f407d457a19f8fdcff3274c5","word_count":145,"reading_time_minutes":1,"sources":[{"url":"https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html","domain":"prnewswire.com"},{"url":"https://finance.yahoo.com/sectors/healthcare/articles/neurocrine-buy-soleno-therapeutics-2-110701181.html","domain":"finance.yahoo.com"},{"url":"https://www.bloomberg.com/news/articles/2026-04-06/neurocrine-to-buy-soleno-therapeutics-for-2-9-billion","domain":"bloomberg.com"}],"translation":{"lang":"cs","id":1392,"title":"Neurocrine Biosciences kupuje Soleno Therapeutics za 2,9 miliardy dolarů a rozšiřuje portfolio léků na vzácná onemocnění","url":"https://techtools.cz/tools/news/clanek/1392-neurocrine-biosciences-kupuje-soleno-therapeutics-za-2-9-miliardy-dolaru-a","api_url":"https://techtools.cz/news-api/v1/articles/1392?lang=cs"},"content":"Neurocrine Biosciences has agreed to acquire Soleno Therapeutics for $53 per share in cash, valuing the deal at approximately $2.9 billion. The acquisition gives Neurocrine access to VYKAT XR (diazoxide choline), a first-in-class therapy approved by the FDA in 2025 for treating hyperphagia — the defining feature of Prader-Willi syndrome, a rare genetic disorder affecting roughly 10,000 patients in the U.S.\n\nVYKAT XR generated $190 million in revenue during its first year on the market, with intellectual property protection extending through the mid-2040s. The offer represents a 34% premium over Soleno's closing price on April 2 and a 51% premium to its 30-day volume-weighted average. Soleno shares surged nearly 40% on the news.\n\nNeurocrine CEO Kyle Gano called the deal a step toward \"delivering life-changing treatments while accelerating revenue growth and portfolio diversification.\" The transaction is expected to close within 90 days pending regulatory approval."}}